Ocular Finding in Alopecia Areata

Status Not yet recruiting

Clinical Trial Summary

Alopecia areata (AA) is a common, idiopathic and sometimes recurrent non-scarring type of hair loss.

Several etiological factors, including psychological, trauma-related, genetic and autoimmune factors have been considered as possible etiological factors . A T cell-mediated autoimmune mechanism in genetically vulnerable individuals is the most acceptable etiology.

Alopecia areata presents clinically with well demarcated patches of non cicatricial hair loss in any hair bearing area with no remarkable gender preference.

Although AA may occur at any age, incidence is high among younger age groups. In fact, it is the most common form of alopecia seen in children. Various clinical patterns of alopecia have been described as patchy, diffuse, reticulate, ophiasis and ophiasis inversus. Depending on the extent of hair loss, it can be classified into alopecia subtotalis, alopecia totalis (complete loss of scalp hair), and alopecia universalis (complete loss of body hair).

National Alopecia Areata Foundation has devised "Severity of Alopecia Tool Score" (SALT score) as a measure of disease severity. Scalp is divided into 4 areas, namely, Vertex-40% of scalp surface area; right and left profiles-18% each and posterior scalp aspect-24%. SALT score is the sum of percentage of hair loss in the above mentioned areas.

Clinical Trial Description

Alopecia areata is now considered a systemic autoimmune disease that may have other serious comorbidities, such as cardiovascular and ocular. However, the results of studies of ocular findings in AA are controversial.

Several ocular alterations have been previously reported in patients with AA ranging from minor punctate opacities to cataract. However, there are contrasting opinions on the significance of these lenticular changes. In addition, Horner syndrome, pupil ectopia, iris atrophy, fundus changes , bilateral keratoconus, iris changes and retinal changes have been reported in AA.

Dermoscopy is a noninvasive, diagnostic tool which visualizes subtle patterns of skin lesions not normally visible to the unaided eye. Characteristic dermoscopic finding of AA included black dots , tapering hair corresponding to " exclamation mark hairs " , broken hairs , yellow dots , and clustered short vellus hairs ( shorter than 10 mm).

Since ocular affection can be a profound morbidity factor in patients with AA, we will search deeply in this study about this correlation in order to conclude the value of ocular screening in each and every patient with AA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03155958
Study type	Observational
Source	Assiut University
Contact	Eman Riad, MD
Phone	00201005298992
Email	E_raid@aun.edu.eg
Status	Not yet recruiting
Phase	N/A
Start date	July 1, 2017
Completion date	January 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05019066` - Oral Herbal Combination Formulation and Hair Growth in Women	N/A
Recruiting	`NCT05502796` - Natural History and Pathogenesis of Alopecia in Children and Adults
Completed	`NCT00981461` - Treatment of Androgenetic Alopecia in Females, 9 Beam	N/A
Terminated	`NCT03709563` - Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss	N/A
Completed	`NCT06095739` - Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002	N/A
Completed	`NCT03351322` - ENERGI-F701 for Female Hair Loss Treatment	Phase 2
Recruiting	`NCT06215469` - Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)	N/A
Completed	`NCT05945979` - Evaluation of the Efficacy of a New Supplement for Hair and Nails - in Vitro, Clinical, Subjective and Instrumental Study	N/A
Not yet recruiting	`NCT05484973` - Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss	N/A
Recruiting	`NCT05319444` - Cleansing Device for the Treatment of Scalp and Hair Conditions	N/A
Completed	`NCT06120933` - A Single-Group Clinical Trial Investigating the Effects of a Hair Vitamin Combination on Hair Growth and Hair Health	N/A
Withdrawn	`NCT04379583` - HairDx Analytical Validation Study
Recruiting	`NCT05970809` - Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss	N/A
Completed	`NCT00947219` - Treatment of Androgenic Alopecia in Males	N/A
Enrolling by invitation	`NCT06174441` - The Effect of 24-week Dietary Intake of Food Supplements on Hair	N/A
Unknown status	`NCT02393040` - Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia	N/A
Completed	`NCT01016964` - Treatment of Androgenetic Alopecia in Females, 12 Beam	N/A
Recruiting	`NCT06283316` - Systemic Treatments for Alopecia Areata Registry
Completed	`NCT04249128` - Nourishing Hair, Skin & Nails Supplement Study (Derm Aid)	Phase 3
Recruiting	`NCT06117293` - Safety and Efficacy Evaluation of the Mosaic Ultra Device	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.